DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, October 12th. The stock was sold at an average price of $124.79, for a total transaction of $623,950.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Andrew K. Balo also recently made the following trade(s):

  • On Friday, September 14th, Andrew K. Balo sold 5,000 shares of DexCom stock. The stock was sold at an average price of $145.17, for a total transaction of $725,850.00.
  • On Tuesday, August 14th, Andrew K. Balo sold 5,000 shares of DexCom stock. The stock was sold at an average price of $124.25, for a total transaction of $621,250.00.

NASDAQ DXCM opened at $133.20 on Wednesday. DexCom, Inc. has a 12-month low of $43.74 and a 12-month high of $148.56. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.89 and a quick ratio of 4.62. The firm has a market capitalization of $12.64 billion, a P/E ratio of -229.66 and a beta of 0.47.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.08. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The business had revenue of $242.50 million during the quarter, compared to the consensus estimate of $205.81 million. During the same quarter last year, the firm posted ($0.16) EPS. DexCom’s revenue was up 42.1% compared to the same quarter last year. On average, sell-side analysts expect that DexCom, Inc. will post -0.47 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Morgan Stanley grew its position in DexCom by 16.3% in the 2nd quarter. Morgan Stanley now owns 5,028,874 shares of the medical device company’s stock valued at $477,644,000 after purchasing an additional 705,072 shares during the period. BlackRock Inc. lifted its stake in DexCom by 5.9% during the 2nd quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock valued at $390,978,000 after acquiring an additional 228,933 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in DexCom by 25.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,225,344 shares of the medical device company’s stock valued at $116,383,000 after acquiring an additional 246,169 shares in the last quarter. Gilder Gagnon Howe & Co. LLC lifted its stake in DexCom by 1.7% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 596,730 shares of the medical device company’s stock valued at $56,677,000 after acquiring an additional 9,919 shares in the last quarter. Finally, Waddell & Reed Financial Inc. lifted its stake in DexCom by 164.8% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock valued at $54,075,000 after acquiring an additional 354,331 shares in the last quarter.

Several brokerages have recently commented on DXCM. Morgan Stanley raised their price objective on shares of DexCom from $130.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 11th. BidaskClub downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, October 3rd. Northland Securities raised shares of DexCom from an “under perform” rating to a “market perform” rating in a research report on Wednesday, September 12th. Robert W. Baird raised their price objective on shares of DexCom from $140.00 to $160.00 and gave the stock a “positive” rating in a research report on Thursday, August 23rd. Finally, Stephens raised their price objective on shares of DexCom from $135.00 to $160.00 and gave the stock an “overweight” rating in a research report on Thursday, August 23rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $123.13.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: Book Value Of Equity Per Share – BVPS Explained

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.